Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This clinical pilot trial is intended to evaluate the feasibility, efficacy and safety of hematopoietic stem cell transplantation (HSCT) from Human Leukocyte Antigen (HLA)-mismatched related donors for children and young adults with hematologic malignancies who lack a suitably matched related or unrelated donor. The methodology will be one that has been successfully utilized in adult patients at Thomas Jefferson University.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwell Health
• Collaborator: New York Blood Center
• Treatments: Cyclophosphamide

Criteria

Inclusion Criteria:

• Acute lymphoblastic leukemia

• Acue myelogenous leukemia

• Myelodysplastic syndrome

• Non-Hodgkin lymphoma

• Chronic myelogenous leukemia

• Adequate lung, liver, renal, cardiac function

• Performance status >70

• Available related donor who is mismatched at ≥ 2 HLA alleles

Exclusion Criteria:

• Available HLA-identical related donor

• HIV positive

• Active uncontrolled infection

• Pregnancy

• Performance status ≤70